Success Metrics

Clinical Success Rate

60.0%

Based on 3 completed trials

Completion Rate

60%(3/5)

Active Trials

5(50%)

Results Posted

67%(2 trials)

Terminated

2(20%)

Phase Distribution

Ph phase_3

10%

Ph phase_1

40%

Ph early_phase_1

10%

Ph phase_2

30%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Early Phase 1First-in-human

1(11.1%)

Phase 1Safety & dosage

4(44.4%)

Phase 2Efficacy & side effects

3(33.3%)

Phase 3Large-scale testing

1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(3)

Terminated(2)

Detailed Status

Completed3

Recruiting3

Active, not recruiting2

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

60.0%

Most Advanced

Phase 3

Trials by Phase

Early Phase 11 (11.1%)

Phase 14 (44.4%)

Phase 23 (33.3%)

Phase 31 (11.1%)

Trials by Status

active_not_recruiting220%

completed330%

recruiting330%

terminated220%

Recent Activity

5 active trials

Showing 5 of 10

recruitingphase_2

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

NCT04576793

active_not_recruitingphase_1

Clinical Trials (10)

Showing 10 of 10 trials

NCT04576793Phase 2

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

Recruiting

NCT05464368Phase 1

R21 Roche: 3-Way Tau Tracers in AD

Active Not Recruiting

NCT03372317

Tau PET in Imaging and Cognition: Healthy Adults From 55-90

Recruiting

NCT04784416Phase 2

Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

Active Not Recruiting

NCT03706261Phase 1

Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

Completed

NCT06999434Phase 1

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Recruiting

NCT03373604Phase 2

Imaging Tau in Alzheimer's Disease and Normal Aging

Completed

NCT06860373Phase 3

LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)

Terminated

NCT03757910Early Phase 1

Brain Imaging in the Diabetes Prevention Program Outcomes Study

Terminated

NCT04566003Phase 1

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Completed

All 10 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 10